ALVR stock icon

AlloVir
ALVR

$0.76
3.8%
 

About: AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.

Employees: 112

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

16,539% more call options, than puts

Call options by funds: $289K | Put options by funds: $1.74K

28% more capital invested

Capital invested by funds: $28.5M [Q4 2023] → $36.4M (+$7.93M) [Q1 2024]

6.5% more ownership

Funds ownership: 36.72% [Q4 2023] → 43.22% (+6.5%) [Q1 2024]

7% less funds holding

Funds holding: 83 [Q4 2023] → 77 (-6) [Q1 2024]

21% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 28

35% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 17

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$1
32%
upside
Avg. target
$1.17
54%
upside
High target
$1.5
97%
upside

3 analyst ratings

positive
0%
neutral
67%
negative
33%
B of A Securities
Jason Zemansky
32%upside
$1
Underperform
Downgraded
26 Dec 2023
Leerink Partners
Mani Foroohar
32%upside
$1
Market Perform
Downgraded
22 Dec 2023
Piper Sandler
Christopher Raymond
97%upside
$1.5
Neutral
Downgraded
22 Dec 2023

Financial journalist opinion